ReviewJournal of gastroenterology2018
Clinical and pathophysiological aspects of type 1 autoimmune pancreatitis.
Review in Journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- IgG4-related disease in gastroenterology: from pathogenesis to clinical management and long-term outcomes.Journal of gastroenterology · 2026Review
- Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2021.Journal of gastroenterology · 2026Article
- The dual role of endoscopic ultrasonography in the diagnosis and treatment of autoimmune pancreatitis with gastric variceal bleeding: A case report and literature review.The Journal of international medical research · 2025Review
- A suspected case of serum IgG4-negative type 1 autoimmune pancreatitis detected due to localized pancreatic duct narrowing: a case report.Clinical journal of gastroenterology · 2024Article
- Pancreatico-renal fistula associated with pancreatic cysts caused by type 1 autoimmune pancreatitis.Clinical journal of gastroenterology · 2024Article
- Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis.Investigational new drugs · 2024Article
- The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD Consortium.RMD open · 2024Article
- Long-term Outcomes after Steroid Pulse Therapy in Patients with Type 1 Autoimmune Pancreatitis.Internal medicine (Tokyo, Japan) · 2023Article
- Review
- Characteristics of mass-forming autoimmune pancreatitis commonly misdiagnosed as a malignant tumor.Frontiers in surgery · 2023Article
- Diagnosis and Treatment of Acute Pancreatitis.Diagnostics (Basel, Switzerland) · 2022Review
- Peripancreatic vascular involvement in patients with type 1 autoimmune pancreatitis.Hepatobiliary surgery and nutrition · 2022Article
- CD163+ M2 Macrophages Promote Fibrosis in IgG4-Related Disease Via Toll-like Receptor 7/Interleukin-1 Receptor-Associated Kinase 4/NF-κB Signaling.Arthritis & rheumatology (Hoboken, N.J.) · 2022Article
- Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma.Cancers · 2022Article
- Histological features of autoimmune pancreatitis and IgG4-related sclerosing cholangitis with a correlation with imaging findings.Journal of medical ultrasonics (2001) · 2021Review
- Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass.Internal medicine (Tokyo, Japan) · 2021Article
- IgG4-related disease: Changing epidemiology and new thoughts on a multisystem disease.Journal of translational autoimmunity · 2021Review
- Steroid-responsive pancreatitides.World journal of clinical cases · 2020Review
- Impact of diet and genes on murine autoimmune pancreatitis.Journal of cellular and molecular medicine · 2020Article
- Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016.Journal of gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In 1995, Yoshida and colleagues proposed the concept of "autoimmune pancreatitis" (AIP), which has recently been recognized as a new pancreatic inflammatory disease. Recent studies have suggested the existence of two subtypes of AIP: type 1, which involves immunoglobulin G4 (IgG4) and is the pancreatic manifestation of IgG4-related disease (IgG4-RD); and type 2, which is characterized by granulocytic epithelial lesions. Type 2 AIP is thought to be rare in Japan. Type 1 AIP is characterized by increased serum IgG4 concentrations, lymphoplasmacytic infiltrations, storiform fibrosis, and obliterative phlebitis. However, although type 1 AIP has become increasingly recognized, many clinical and basic issues remain to be solved. This review provides an overview of the recent clinical and basic knowledge of type 1 AIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.